Release
2026/10/29
OSAKA, Japan, October 29, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi China (Head Office: Shanghai, China; Chairman and CEO: Hirofumi Nagatome), a Shionogi group company in China, has entered into a share transfer agreement (hereafter, the "Agreement") with Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. (Head Office: Zhejiang, China; Chairman: Shaojun Chen; hereafter, "Gaozhi") regarding the transfer of shares in Shenzhen Liancheng Pharmaceutical Co., Ltd. and Nanjing Chang'ao Pharmaceutical Co., Ltd., which operate Shionogi's generic drug business in China.
Shenzhen Liancheng Pharmaceutical Co., Ltd. and Nanjing Chang'ao Pharmaceutical Co., Ltd. are Shionogi group companies engaged in the development, manufacturing, and sales of generic drugs in China. The generic drug business has served as a foundation for Shionogi's business in China for many years. In recent years, however, in response to changes in the business environment, Shionogi has been transitioning its business in China toward a business model centered on innovative medicines. The Agreement represents an initiative to advance the structural transformation of Shionogi's business in China.
In China, Shionogi has been steadily expanding its business centered on innovative medicines, including obtaining regulatory approvals for Shionogi-discovered products such as cefiderocol, a siderophore cephalosporin antibiotic, and naldemedine, a treatment for opioid-induced constipation.¹˒² Through the Agreement, Shionogi will further accelerate the allocation of management resources to its innovative medicine business and further strengthen the competitiveness of its business in China.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
References
1. Press release on January 8, 2026
Approval for Cefiderocol in China
2. Press release on May 29, 2025
Notice Regarding Approval of Naldemedine for Opioid-Induced Constipation in China